Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial

被引：0

作者：

Broeckelmann, Paul J. ^{[1
,2
,4
]}

Teesink, Sophie ^{[5
]}

Visser, Lydia ^{[5
]}

Voltin, Conrad-Amadeus ^{[6
]}

Kaul, Helen ^{[7
,8
]}

Schloesser, Hans ^{[8
,9
]}

Kroesen, Bart-Jan ^{[10
]}

Kobe, Carsten ^{[6
]}

Borchmann, Peter ^{[1
,2
,3
,4
]}

Diepstra, Arjan ^{[5
]}

Plattel, Wouter ^{[11
]}

机构：

[1] Univ Cologne, Med Fac, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dep Internal Med 1, Cologne, Germany

[3] Univ Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Dusseldor, Cologne, Germany

[4] Univ Cologne, German Hodgkin Study Grp GHSG, Cologne, Germany

[5] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands

[6] Univ Hosp Cologne, Dept Nucl Med, Cologne, Germany

[7] Univ Cologne, Med Fac, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

[8] Univ Hosp Cologne, Cologne, Germany

[9] Univ Cologne, Fac Med, Dept Gen Visceral Canc & Transplantat Surg, Cologne, Germany

[10] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Groningen, Netherlands

[11] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

来源：

关键词：

D O I：

10.1182/blood-2024-201547

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3044 / 3045

页数：2